DoctorMohammed Salahudeen

Senior Lecturer in Clinical Pharmacy

Pharmacy

  • Senior Lecturer in Clinical Pharmacy
    Pharmacy
  • +61 3 6226 1837 (Work)
  • School of Pharmacy and Pharmacology, Room 4014, Sandy Bay Campus, TAS, Australia

RESEARCH SUMMARy

Dr Salahudeen’s research expertise spans geriatrics, pharmacoepidemiology, aged care, quality use of medicines, and medication safety, with an expanding focus on the use of artificial intelligence to enhance clinical decision-making and medication safety systems. He has a special research interest in issues related to medication use in dementia and has published several papers on this topic.

 

His research is at the forefront of “anticholinergic science”, where he investigates the risks, burden, and optimisation of anticholinergic prescribing in older adults. He has been instrumental in advancing the use of AI-driven approaches and digital decision-support tools to improve medication safety and deprescribing practices in clinical pharmacy.

 

He has been instrumental in advancing the use of AI-driven approaches and digital decision-support tools to improve medication safety and deprescribing practices in clinical pharmacy.

FUNDED PROJECTS

  • GRANT
    From mood to memory: how antidepressants impact on Alzheimers disease progression.
    1 Mar 2026 - 1 Mar 2028
    People funded by this grant:
    • Doust Y,
    • Ziebell J,
    • Salahudeen M
    Project Total: $85,000; Depression is a common neuropsychiatric symptom in individuals with Alzheimers disease (AD), often emerging in the early to middle stages of the condition. Selective Serotonin Reuptake Inhibitors (SSRIs) are frequently prescribed to manage depressive symptoms due to their favourable safety profile and tolerability in older adults. Emerging evidence suggests that SSRIs may influence AD pathology and progression, yet their precise role remains unclear. This study aims to investigate the effects of SSRIs on pathological and functional outcomes in AD, integrating clinical and preclinical approaches to enhance translational relevance. We will analyse large-scale clinical databases containing information on SSRI use, cognitive performance, neuroimaging, and serum biomarkers to identify which SSRIs are associated with reduced disease burden in Australians living with AD. These findings will inform the design of mechanistic studies using male and female 3xTg AD mice, a well-characterised model of AD. Mice will receive either acute or chronic SSRI treatment, with comparisons made to untreated controls. Monthly assessments of cognitive and motor function will be conducted, alongside serial blood sampling for biomarker analysis. Following 8 weeks of SSRI exposure, brain tissue will be collected to evaluate amyloid and tau pathology, blood-brain barrier integrity, and glial reactivity. This approach will allow us to determine whether SSRI exposure alters key pathological features of AD and identify potential mechanisms underlying these effects. By directly linking clinical observations with mechanistic outcomes, this research will clarify the role of SSRIs in AD progression and support the development of evidence-based strategies for managing depression in dementia. Funded by: Dementia Australia Research Foundation Ltd - Project Grant ($84,981); University of Tasmania ($231,125).
  • GRANT
    Optimising Oral Anticoagulant Use in Hospitlised Patients with Atrial Fibrillation: An Opportunity Enhancement Intervention.
    1 Jan 2025 - 30 Dec 2026
    People funded by this grant:
    • Bezabhe W,
    • Peterson G,
    • Dwyer N,
    • Mirkazemi C,
    • Black DA
    Project Total: $25,000; Appropriate use of oral anticoagulants (OACs) reduces the risk of stroke and death by 64% and 25%, respectively. In our previous study that compared OAC prescribing at admission (community) and discharge (hospital), we confirmed that, in routine care, the RHH team improved the guideline appropriateness of OAC use in patients with atrial fibrillation. However, half of the patients with guideline-inappropriate OAC prescribing at admission were discharged without correction. The efficiency of correcting inappropriate OAC use varied significantly across RHH admission wards. An intervention that enhances the likelihood of the RHH care team to correct inappropriate OAC use is required. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($25,000); University of Tasmania.
  • GRANT
    From Reduction to Optimisation: Integrating an Alert System for Anticholinergic Medication in the Elderly
    1 Jan 2024 - 30 Sep 2026
    People funded by this grant:
    • Salahudeen M,
    • Peterson G,
    • Adamczewski B,
    • Wilson A,
    • Bayer G
    Project Total: $24,944; The safe and quality use of medicines is a new National Health Priority Area, with significant health consequences, particularly for older people. This innovative project will implement and evaluate a sticker alert system in the patients progress notes to optimise anticholinergic medication therapy to reduce the risk of adverse outcomes. The project also aims to modify the existing anticholinergic medications rating score (high=3, moderate=2, low=1) for the Australian context through a modified Delphi process. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,944); University of Tasmania.
  • GRANT
    Geriatric Antipsychotic Stewardship (GApS) Program for Behavioural and Psychological Symptoms of Dementia and Delirium: a pilot study
    1 Jan 2024 - 30 Nov 2027
    People funded by this grant:
    • Hoyle D,
    • Peterson G,
    • Fasnacht M,
    • Adamczewski B,
    • Salahudeen M
    Project Total: $9,999; The high prevalence of antipsychotic use in aged care has led to concern of inappropriate sedation. Emerging evidence suggests that hospitalisation is contributing to this issue. This study will trial a geriatric antipsychotic stewardship program for non-psychiatric admissions of older people to improve the use and review of antipsychotics during and after hospitalisation. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,999); University of Tasmania ($9,529).
  • GRANT
    Hospitalisation as an opportunity to optimise anticoagulant treatment in patients with atrial fibrillation
    1 Jan 2023 - 30 Jun 2024
    People funded by this grant:
    • Bezabhe W,
    • Peterson G,
    • Radford J,
    • Boland C,
    • Salahudeen M
    Project Total: $9,985; Our recent studies indicate that many community-based patients with atrial fibrillation and a high stroke risk still do not receive the recommended anticoagulant therapy. This study will examine anticoagulant use in patients with atrial fibrillation upon admission and discharge and determine whether hospitalisation represents an opportunity to improve the quality of care. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,985); University of Tasmania.
  • GRANT
    Intervention to lessen anticholinergic drug burden in hospitalised older adults
    1 Jan 2022 - 30 Jun 2023
    People funded by this grant:
    • Salahudeen M,
    • Peterson G,
    • Adamczewski B,
    • Hoyle D,
    • McKenzie D
    Project Total: $9,996; Drugs with anticholinergic properties carry significant risks in older people, including extended hospital admissions, falls, dementia and increased mortality. However, the pattern of anticholinergic drug prescribing in Tasmania is not yet known. This study will investigate the effectiveness of an educational intervention to improve prescribing of anticholinergic-type drugs. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,996); University of Tasmania.
  • GRANT
    Adverse drug reaction-related hospital admission in elderly Australians with dementia
    1 Jan 2020 - 30 Jun 2021
    People funded by this grant:
    • Parameswaran Nair N,
    • Bereznicki L,
    • Adamczewski B,
    • Salahudeen M,
    • Bereznicki B
    Project Total: $9,985; Dementia is a significant risk factor for serious side effects of medicines or adverse drug reactions (ADRs). This prospective study will investigate and identify the prevalence and risk factors for ADR-related hospital admissions in elderly patients with dementia or cognitive impairment. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,985); University of Tasmania.
  • NON-UTAS AFFILIATED
    Risks associated with polypharmacy and hyper-polypharmacy in older individuals: Addressing the deficiencies of previous polypharmacy research
    University of Otago1 Jan 2016 - 31 Dec 2017
    People funded by this grant:
    • Salahudeen M
    Project Total: $140,000; Funded by: University of Otago